StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Alectinib

HCID 49806720
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1256580-46-7
Standard-SMILES
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
InChIKey
KDGFLJKFZUIJMX-UHFFFAOYSA-N
Summenformel
C30H34N4O2
Durchschnittliche Molmasse
482,6 g/mol
Monoisotopische Masse
482,26817634

Überblick

Alectinib is an organic heterotetracyclic compound that is 6,6-dimethyl-5,6-dihydro-11H-benzo[b]carbazol-11-one carrying additional cyano, 4-(morpholin-4-yl)piperidin-1-yl and ethyl substituents at positions 3, 8 and 9 respectively. Used (as the hydrochloride salt) for the treatment of patients with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is a nitrile, a member of piperidines, an organic heterotetracyclic compound, a member of morpholines and an aromatic ketone. It is a conjugate base of an alectinib(1+).

Namen und Bezeichner

Bevorzugter Name
Alectinib
IUPAC
9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
Englischer Name
Alectinib
Summenformel
C30H34N4O2
Molmasse
482.62

Namen und Synonyme

Alectinib1256580-46-7CH5424802CH 5424802AF-802RO5424802CH-5424802AF8029-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrileAF 802LIJ4CT1Z3YRO-5424802
Weitere Namen anzeigen
AlecensaAlecitinibalectinbAlectinib (CH5424802)9-ETHYL-6,6-DIMETHYL-8-(4-MORPHOLINOPIPERIDIN-1-YL)-11-OXO-6,11-DIHYDRO-5H-BENZO[B]CARBAZOLE-3-CARBONITRILECS-217canna*RG-7853Aletinib
9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-CHEBI:90936DTXSID50154840RG78539-ETHYL-6,6-DIMETHYL-8-[4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL]-11-OXO-5H,6H,11H-BENZO[B]CARBAZOLE-3-CARBONITRILE5H-BENZO(B)CARBAZOLE-3-CARBONITRILE, 9-ETHYL-6,11-DIHYDRO-6,6-DIMETHYL-8-(4-(4-MORPHOLINYL)-1-PIPERIDINYL)-11-OXO-alectinibum

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete Struktureigenschaften

XLogP
5,2
Polarare Oberfläche (TPSA)
72,4 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
3
Schwere Atome
36
Formalladung
0
Komplexität
867

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors

EMA approved medicines: Human medicine

Dissociation Constants7.05

Physikochemische Eigenschaften

Schmelzpunkt
274 · 274-276°C
Siedepunkt
722.5 · 722.5±60.0 °C(Predicted)
Dichte
1.28 · 1.28
storage temp.
-20 ° · -20°
Löslichkeit
Soluble in DMSO (up to 5 mg/ml with warming).
pka
13.7 · 13.70±0.40(Predicted)
Aggregatzustand
solid
Farbe
White
Stabilität

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 66.7% (2 of 3) of all reports.

Warning

H341 (33.3%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]

P203, P260, P280, P318, P319, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationREACH registered substance: 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile (EC: 821-541-6)
Hazard Classes and CategoriesMuta. 2 (33.3%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

In preregistration trials of alectinib, ALT elevations occurred in up to 60% of patients, but values above 5 times the upper limit of normal (ULN) were found in only 1% to 5%. Alectinib therapy was also associated with frequent elevations in alkaline phosphatase (47%) and bilirubin (39%), but these abnormalities were usually transient, asymptomatic, and mild-to-moderate in degree. Clinically apparent liver injury with jaundice was rare, but cases were reported and at least 2% of alectinib treated subjects discontinued therapy early because of liver test abnormalities. In subsequent controlled trials, liver test abnormalities arose in 41% of alectinib treated patients and were above five times ULN in 8%, leading to early discontinuation in 4%, and 3 patients were judged to have drug induced liver injury.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

L01XE36

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingAlectinib and its major metabolite M4 are >99% bound to human plasma proteins.
Mechanism of Action · 1 Eintrag

Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Both alectinib and its major active metabolite M4 demonstrate similar in vivo and in vitro activity against multiple mutant forms of ALK.

Biological Half-LifeThe mean elimination half life is 33 hr for alectinib and 31 hr for M4.
Metabolism/Metabolites · 1 Eintrag

Alectinib is metabolized by CYP3A4 to its major active metabolite M4. M4 is then further metabolized by CYP3A4. Both alectinib and M4 demonstrate similar in vivo and in vitro activity. In vitro studies suggest that alectinib is not a substrate for P-gp while M4 is.

FDA Pharmacological Classification · 5 Einträge

LIJ4CT1Z3Y

ALECTINIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Kinase Inhibitors

Alectinib is a Kinase Inhibitor. The mechanism of action of alectinib is as a Kinase Inhibitor.

MeSH Pharmacological ClassificationProtein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.
Absorption, Distribution and Excretion

Zugehörige Reaktionen

3
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 61876
HRID 61876als Produkt
Reaktionsgleichung von HRID 2202445
HRID 2202445als Edukt
Reaktionsgleichung von HRID 2275252
HRID 2275252als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
1256580-46-7、1256589-74-8
PubChem CID
49806720
DTXSID
DTXSID50154840
ChEMBL
CHEMBL1738797
ChEBI
CHEBI:90936
UNII
LIJ4CT1Z3Y
EC Number
821-541-6
Nikkaji
J3.001.965B
1 year · Stable for 1 year from date of purchase as supplied. Solutions are not stable and should be prepared fresh daily.
InChIKey
KDGFLJKFZUIJMX-UHFFFAOYSA-N
SMILES
N1C2=C(C=CC(C#N)=C2)C2=C1C(C)(C)C1=CC(N3CCC(N4CCOCC4)CC3)=C(CC)C=C1C2=O
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation

Sicherheitsdaten

hs_code
2934999090
· 4 Einträge

Alectinib reached maximal concentrations at 4 hours following administration of 600 mg twice daily under fed conditions in patients with ALK-positive NSCLC. The absolute bioavailability was 37% in the fed state. A high-fat, high-calorie meal increased the combined exposure of alectinib and its major metabolite M4 by 3.1-fold following oral administration of a single 600 mg dose.

When radioactively labeled, 98% of radioactivity was found in feces with 84% of that amount excreted as unchanged alectinib and 6% as M4. Less than 0.5% was found to be recovered in urine.

4016 L

The apparent clearance is 81.9L/hr for alectinib and 217 L/hr for M4.

Anwendungen

BeschreibungAlectinib is another selective ALK inhibitor that is able to overcome resistance mutations from prior crizotinib exposure [38].

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

4-Morpholinopiperidine9-broMo-6,6-diMethyl-8-(4-Morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile9-ethynyl-6,6-diMethyl-8-(4-Morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrileDiethylzinkTrimethylsilylacetylenMorpholin

Nachgelagerte Produkte

Alectinib Hydrochloride
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: An organic heterotetracyclic compound that is 6,6-dimethyl-5,6-dihydro-11H-benzo[b]carbazol-11-one carrying additional cyano, 4-(morpholin-4-yl)piperidin-1-yl and ethyl substituents at positions 3, 8 and 9 respectively. Used (as the hydr chloride salt) for the treatment of patients with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer.